2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-176251
    CBP/p300-IN-22 98%
    CBP/p300-IN-22 is a selective CBP/EP300-BRD inhibitor with an IC50 of 4 nM. CBP/p300-IN-22 is highly selective over BRD4(1). CBP/p300-IN-22 reduces TNF-α-induced cytokine expression and subsequent immune cell recruitment by inhibiting NF-κB signaling, and has anticancer activity. CBP/p300-IN-22 can be used for the research of rheumatoid arthritis (RA) and other TNF-α-mediated inflammatory conditions.
    CBP/p300-IN-22
  • HY-176255
    TBK1 degrader-4 98%
    TBK1 degrader-4 (Compound 30) is a molecular glue degrader targeting TBK1. TBK1 degrader-4 effectively inhibits cyst growth, alleviates inflammation, and reduces the levels of pro-inflammatory factors such as Ccl2, IFNβ, and IL-6. TBK1 degrader-4 is promising for research of autosomal dominant polycystic kidney disease (ADPKD).
    TBK1 degrader-4
  • HY-176265
    DDS5 2871481-31-9 98%
    DDS5 is a CD28 inhibitor with a kd of 175.57 µM. DDS5 significantly inhibits CD28-CD80 interaction (IC50: 332 µM). DDS5 can be used for research of immune-mediated diseases, including inflammatory bowel disease and rheumatoid arthritis.
    DDS5
  • HY-176273
    RORγt inverse agonist 35
    RORγt inverse agonist 35 (Compound 22) is a RORγt inverse agonist with an IC50 of 1.51 μM. RORγt inverse agonist 35 significantly inhibits Th17 differentiation and proinflammatory properties in human CD4+ T cells. RORγt inverse agonist 35 can be used for research of Th17-driven autoimmune diseases, such as psoriasis, multiple sclerosis, and inflammatory bowel disease (IBD).
    RORγt inverse agonist 35
  • HY-176274
    FASN/SCD-IN-1 3063509-61-2 98%
    FASN/SCD-IN-1 is a Silybin (HY-N0779A) derivative, an orally active inhibitor of Fatty Acid Synthase (FASN)/Stearoyl-CoA Desaturase (SCD). FASN/SCD-IN-1 has shown in vitro activity in inhibiting lipid deposition, reducing FASN and SCD transcriptional levels, and exhibiting antioxidant, anti-inflammatory, and anti-fibrotic activities. FASN/SCD-IN-1 has demonstrated significant hepatoprotective effects in a rat model of acute liver injury. FASN/SCD-IN-1 ameliorates the pathological features of MASH liver, including steatosis, inflammation, and fibrosis in a mouse model of myeloproliferative steatohepatitis (MASH). FASN/SCD-IN-1 can be used to study MASH.
    FASN/SCD-IN-1
  • HY-176298
    Tegacorat 2409551-99-9
    Tegacorat (Compound 447) is a glucocorticoid receptor agonist with an EC50 ＜ 100 nM. Tegacorat can be used in the research of inflammatory diseases.
    Tegacorat
  • HY-176301
    Tetranor-PGDM lactone
    Tetranor-PGDM lactone (Tetranor-prostaglandin D metabolite lactone) is a urinary metabolite of PGD2 (HY-101988). Prostaglandin D2 (PGD2) is one of the most potent endogenous sleep promoting substances. PGD2 plays a protective role by suppressing inflammation.
    Tetranor-PGDM lactone
  • HY-176407
    ZYH-23 98%
    ZYH-23 is a potent necroptosis inhibitor. ZYH-23 blocks necroptosis by inhibiting RIPK1, RIPK3, and MLKL phosphorylation via HSP90 targeting.
    ZYH-23
  • HY-176425
    E3 Ligase Ligand-linker Conjugate 186 2789680-19-7 98%
    E3 Ligase Ligand-linker Conjugate 186 is a CRBN E3 ligase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 186 can be used to synthesize PROTAC SJ10542 (HY-145696).
    E3 Ligase Ligand-linker Conjugate 186
  • HY-176456
    PARP14 inhibitor 2 3064731-00-3
    PARP14 inhibitor 2 (Compound 3) is an orally active and highly selective PARP14 inhibitor with an IC50 value of <30 nM. PARP14 inhibitor 2 inhibits the mono-ADP-ribosyltransferase activity of PARP14 and regulates IFN-γ and IL-4 signaling, reversing protumor macrophage polarization and inhibiting anti-tumor inflammatory responses. PARP14 inhibitor 2 is promising for research of PARP14-related diseases such as tumors, atopic dermatitis and autoimmune diseases.
    PARP14 inhibitor 2
  • HY-176465
    CES2A-IN-3 3037959-47-7 98%
    CES2A-IN-3 (Compound 9d) is a potent serine-targeting covalent human carboxylesterase 2A (hCES2A) inhibitor with an IC50 value of 0.12 nM. CES2A-IN-3 is promising for research of diarrhea and ulcerative colitis.
    CES2A-IN-3
  • HY-176500
    Spns2-IN-3 3035022-30-8
    Sphingolipid E is a synthetic pseudoceramide sphingolipid similar to type 2 ceramide with a metastable lamellar structure. Sphingolipid E ??can be used as a potential drug carrier to control the penetration of molecules as a lipid component of the intercellular space of the stratum corneum.
    Spns2-IN-3
  • HY-176520
    PDE4-IN-29 2815361-45-4
    PDE4-IN-29 (Compound 55) is an orally active and selective PDE4 inhibitor (including subtypes such as PDE4A1, PDE4B2, PDE4D3) with IC50s of <5 nM against PDE4D3. PDE4-IN-29 inhibits the degradation of cyclic adenosine monophosphate (cAMP), increases intracellular cAMP levels, suppressing the release of inflammatory factors such as TNF-α. PDE4-IN-29 is promising for research of inflammatory diseases including psoriasis, atopic dermatitis, and chronic obstructive pulmonary disease.
    PDE4-IN-29
  • HY-176525
    PLC-β-IN-1
    PLC-β-IN-1 (Compound 8a) is a PLCβ inhibitor. PLC-β-IN-1 exerts anti-airway contraction activity by inhibiting PLCβ and its downstream signaling pathways, and can enhance the airway relaxation effect of β-agonists. PLC-β-IN-1 can be used in the study of asthma.
    PLC-β-IN-1
  • HY-176527
    (Rac)-TUL01101 2411222-71-2
    (Rac)-TUL01101 (Compound I) is a selective JAK kinase inhibitor. (Rac)-TUL01101 can be used in the research of various diseases such as rheumatoid arthritis, atopic dermatitis, and alopecia areata.
    (Rac)-TUL01101
  • HY-176535
    KB-0118 2648377-08-4 98%
    KB-0118 (BBC0115) is an orally active BET bromodomain inhibitor. KB-0118 selective binds to BRD2 and BRD4 over BRD3, with Kd values of 36.7 μM for BRD2 BD1 and 47.4 μM for BRD4 BD1. KB-0118 inhibits pro-inflammatory cytokines, including TNF, IL-1β, and IL-23a and selectively suppresses Th17 cell differentiation. KB-0118 modulates Th17-driven inflammation occurs through epigenetic suppression of BRD4, confirmed by downregulation of STAT3 and BRD4 target genes. KB-0118 has immunomodulatory effects in inflammatory bowel disease (IBD) model.
    KB-0118
  • HY-176544
    AM11638 3054510-97-0
    AM11638 is an endocannabinoid analog targeting cannabinoid receptors (CB1 and CB2 receptors) with analgesic effects. AM11638 is promising for research of neurological diseases and inflammation-related diseases.
    AM11638
  • HY-176548
    PY-PAP 2765218-57-1 98%
    PY-PAP is a photoactivatable affinity probe and a derivative of PY-60 (HY-141644). PY-PAP retains the cellular function of activating YAP transcriptional activity. In 293A cells, PY-PAP can label cathepsin D (CTSD) and annexin A2 (ANXA2) through ultraviolet crosslinking and click reactions. PY-PAP plays a key role in identifying ANXA2 as the specific target of PY-60.
    PY-PAP
  • HY-176553
    KBD4466 3023713-87-0 98%
    KBD4466 is an orally active potent TLR7 and TLR8 inhibitor with IC50s of 0.9 nM and 2.8 nM, respectively. KBD4466 inhibits the expression of inflammatory cytokines IL-6 and IFN-α. KBD4466 improves disease progression and survival in the BXSB/MpJ mouse model of Systemic Lupus Erythematosus (SLE). KBD4466 can be used in the study of autoimmune diseases.
    KBD4466
  • HY-176554
    sEH-IN-21 3084814-46-7 98%
    sEH-IN-21 is an orally active sEH inhibitor with IC50s of 0.1 nM for hsEH and msEH. sEH-IN-21 potently inhibits NF-κB signaling pathways. sEH-IN-21 shows a strong anti-inflammatory activity, decreases the release of IL-6 and TNF-α and maintained the integrity of the intestinal barrier. sEH-IN-21 can be used for the study of inflammatory bowel disease (IBD).
    sEH-IN-21
Cat. No. Product Name / Synonyms Application Reactivity